Our medications are changing the lives of the patients we serve. Currently, within the United States, oncology treatment and care are our immediate focus. We have four medicines available:
Globally we have a broad portfolio of medicines which are prescribed in almost 150 countries. The availability, name and indicated use of our medicines may vary globally. Each country has different drug approval processes for the specific purpose of the medication; please consult local regulators for more information. To learn more about which Servier products are available in your country visit Our Servier Medicines.
Our Focus on Value
The patients we serve are our top priority. We are committed to providing the best value for their care. We work to establish a medicine's price that reflects the value it offers to patients and the healthcare system, based on a range of factors including impact on patients and their disease relative to other available treatments and the potential to reduce additional health care costs, such as hospital stays. We remain committed to ensuring our treatments offer real value as determined by our patients' outcomes, choices and advanced care.
More from Servier
Acute lymphoblastic leukemia is a rapidly progressing cancer that starts in the bone marrow and spreads to the blood. It represents 12 percent of all leukemia cases worldwide, and about 80 percent of childhood leukemia cases.Learn More
Acute myeloid leukemia is a cancer of the blood and bone marrow marked by rapid disease progression and is the most common acute leukemia affecting adults with approximately 20,000 new cases estimated in the U.S. each year.Learn More
Research & Development
We invest in innovative research and development through our own development or partnerships to best address the unmet needs of patients.Learn More